Learn
A little clarity for your next decision.
Loading your learning library…
Investor WorkspaceWelcome, there!Log Out
Investor WorkspaceA little clarity for your next decision.
By Jerry Baker
Life-sciences real estate provides space for research, testing, development, or production connected to biology and health. This guide explains how to review these properties for a 1031 exchange, including tenant funding, laboratory design, leasing costs, safety responsibilities, and debt. Scientific importance does not guarantee that a tenant can pay rent or that a specialized building will be easy to re-lease.
A research laboratory, a computational office, a testing facility, and a manufacturing plant are different real estate products. Ask what the current tenant does and which systems it needs. A broad “life sciences” label can hide large differences in cost and future usefulness.
Wet-lab space generally supports work involving physical materials and laboratory systems, while dry-lab or computational work may have different needs. Even within those broad categories, requirements vary. Ask qualified engineers and sector specialists to assess the actual space rather than assuming one standard laboratory design.
Also define the ownership structure. The investor may own real estate through a lease-based arrangement without owning the tenant's research or products. Rent depends on the tenant's ability to perform under the lease. The scientific story and the property investment should be reviewed separately.
An established company with product revenue differs from an early-stage research firm funded by investors or grants. Both can rent laboratory space, but their sources of cash and risks are different. Ask how the tenant funds operations today and what it expects to rely on next.
Review the legal tenant, parent relationships, guarantees, and financial reporting rights. A famous partner, investor, or university connection does not necessarily guarantee the lease. Confirm which entity is obligated and what resources stand behind that obligation.
Ask how much of the tenant's activity depends on one program, customer, contract, or funding source. A diversified research platform may still rely on a small number of important milestones. The landlord needs to understand that concentration without pretending to predict scientific success.
Cash runway is an estimate of how long available funds can support spending under stated assumptions. Ask for the calculation, date, cash restrictions, and expected changes in spending. A simple division can be useful, but it is not a commitment that future costs will remain unchanged.
Suppose a hypothetical tenant has $30 million of unrestricted cash and spends a net $2 million per month. The simple runway is fifteen months. If spending rises to $3 million per month, it falls to ten months. Neither number includes a future financing round unless that funding is actually available.
Review lease obligations beyond the runway. A ten-year lease does not create ten years of tenant cash. Ask what financing, revenue, or cost changes must occur to support the business, and what the landlord can do if those events do not happen.
NIH RePORTER allows users to search NIH-funded projects, investigators, publications, and patents. It can provide context for a research community or a specific funded project. An award record is not a guarantee of a company's unrestricted cash, future funding, commercial success, or rent payment. [8]
Match the recipient entity, project period, and funding conditions to the tenant under review. A grant to a university researcher may not belong to the company leasing the building. Announced funding may also have restrictions or timing that matter to cash availability.
Ask for a clear distinction between committed funds, proposed grants, expected investment rounds, and hoped-for product revenue. Those items have different levels of certainty. The forecast should not treat all of them as cash already in the bank.
FDA describes drug development as a process that can include discovery, preclinical work, clinical research, agency review, and post-market monitoring. A tenant working at an early stage has not thereby secured approval or commercial revenue. The landlord's review should not equate promising research with a proven product. [10]
Ask how a delay, unsuccessful result, or change in strategy could affect staffing, spending, and space needs. The real estate analysis can address those financial consequences without making a clinical judgment. Qualified scientific and regulatory specialists should evaluate claims that require their expertise.
A company may succeed and still change its footprint. It could outsource production, move closer to partners, or need a different building. Conversely, it may remain in the space while changing projects. The lease and building's flexibility matter alongside the tenant's business outlook.
A location near universities, hospitals, skilled workers, suppliers, and other research firms may offer practical benefits. Ask which relationships the tenant actually uses and why the location matters. A list of nearby institutions does not prove that the property receives direct demand from them.
Review commuting patterns, housing costs, transport, and access to specialized services. A cluster can attract tenants while also creating competition for workers and space. The property's position within that cluster matters more than the city's reputation alone.
Look at current leasing transactions for comparable laboratory space. Separate research, manufacturing, and office-heavy facilities. A large new campus may not be a useful rent comparison for an older building with different systems or smaller suites.
Review available, under-construction, and proposed space by readiness and specification. A shell, a fitted laboratory, and a facility with specialized approvals are not equivalent. Ask what work a tenant would need before occupying each alternative.
Include sublease space where relevant. A tenant reducing its footprint can create competition even if it remains liable on the original lease. Compare remaining term, condition, furniture or equipment, and concessions with the subject property's offering.
Ask whether the sponsor's market study separates announced projects from funded construction. Future supply can change, and a broad pipeline number may overstate or understate competition at the relevant date. The forecast should explain the evidence and uncertainty.
Review ventilation, power, cooling, water, waste handling, floor loading, vibration, ceiling height, and service access as relevant. The needed combination depends on the tenant's work. More capacity is not automatically valuable if likely users do not need it or cannot afford the operating cost.
Ask which systems are part of the base building and which belong to the tenant. Identify spare capacity and the cost of expansion. A claim that a building is “lab ready” should be supported by specific systems, approvals, and a clear description of what remains to be installed.
Review maintenance and replacement responsibility. Specialized systems can create large costs and require qualified service providers. The lease should be matched with an inspection-based capital plan, including the possibility that a tenant fails to perform its duties.
CDC and NIH's Biosafety in Microbiological and Biomedical Laboratories is advisory guidance built around risk assessment and appropriate practices, equipment, and facilities. Its sixth edition is not itself a blanket regulatory approval for a property. The current CDC page identifies it as guidance rather than a regulatory document. [7]
For an investment review, ask which qualified professionals have assessed the proposed use, required approvals, and facility suitability. Do not infer that a marketing label establishes compliance. The details depend on the work, materials, equipment, jurisdiction, and responsible operator.
The landlord should understand its contractual duties and the process for monitoring permitted uses. That does not require investors to receive sensitive research protocols. The useful records are the relevant approvals, responsibilities, inspection findings, and evidence that identified issues are addressed.
A new laboratory tenant may require design, permits, specialized construction, equipment connections, testing, and commissioning before rent begins. Ask for the scope and the owner-funded portion. A tenant improvement allowance may not cover every base-building upgrade.
Review who pays overruns, owns improvements, and bears delay risk. If the owner commits to deliver a specific system or condition, it needs funding and an achievable schedule. A signed lease can create a major cash obligation before it creates income.
Compare effective rent after concessions, improvement costs, commissions, and other charges. A high stated rent may compensate for expensive space delivery. The investor should see the net economics over the lease term rather than only the first full year of rent.
Suppose a hypothetical owner leases 30,000 square feet and agrees to fund $150 per square foot of improvements. The allowance alone is $4.5 million. At annual base rent of $60 per square foot, full annual base rent is $1.8 million before expenses and other adjustments.
The improvement allowance equals two and a half years of that gross base rent. Commissions, free rent, base-building work, financing, and other costs would add to the cash needs. These figures are illustrative, not current laboratory-market pricing.
Ask when the $4.5 million must be funded and what happens if construction is delayed or the tenant's finances weaken. The comparison shows why strong headline rent can coexist with substantial execution risk. The owner needs both a good lease and the resources to deliver it.
Laboratory operations can require systems that run for long hours or serve specialized loads. Review actual usage and service requirements rather than applying an ordinary office budget. Ask which costs are metered, reimbursed, capped, or absorbed by ownership.
Compare the lease's expense provisions with the tenant's operations. A change in use or intensity may affect utilities and maintenance. The owner should understand whether the contract allows appropriate recovery and whether the tenant has the resources to pay.
Also review reliability needs. A utility interruption can affect the tenant's business even if the building has little physical damage. Ask about the division of duties, backup arrangements, insurance, and limits on landlord liability under the actual agreements.
Ask about prior uses, current permitted activities, waste handling, and relevant environmental reports. A laboratory building requires a review of the actual history and operations, not an assumption that all research facilities have the same exposure.
EPA's All Appropriate Inquiries framework addresses environmental conditions and potential contamination liability. Read report findings and recommended follow-up, and have counsel address legal protections and continuing obligations. An assessment is not a guarantee that every condition has been discovered. [9]
Read restoration and decommissioning provisions. Ask what the tenant must remove, clean, document, or leave in place at lease end. Review security supporting those obligations and the owner's practical plan if the tenant cannot perform. A contractual promise needs resources behind it.
Some laboratory improvements may be useful to many users; others may fit only a narrow process. Ask a qualified leasing and engineering team to identify likely replacement tenants and the work each would require. A specialized building's reuse value should not be assumed from its original construction cost.
Review whether space can be divided, combined, or converted without major system changes. Multi-tenant use may require separate utilities, access, and other work. A flexible floor plan is only one part of flexibility.
Estimate vacancy, commissions, improvements, and operating costs during the transition. Include any decommissioning that ownership might need to fund. The reserve should be tested against that estimate rather than based only on a standard percentage of rent.
Several tenants may rely on the same funding environment, research area, or local institution. Their legal names can differ while their economic risks overlap. Review sources of cash, business stages, and major milestones across the rent roll.
A large established tenant can reduce some funding uncertainty while creating concentration if it provides most of the rent. A group of smaller firms can spread lease exposure while increasing turnover and credit-review work. Neither structure is automatically safer.
Map lease expirations and expected capital needs by year. A portfolio can face a difficult period if several tenants need new financing or make space decisions at the same time. The review should show those clusters rather than smoothing them into an average term.
Read interest rate, maturity, amortization, reserve requirements, covenants, and cash-sweep provisions. Ask how tenant credit changes, vacancy, or unfinished improvements can affect the loan. The lender may require cash to remain at the property before there is a payment default.
Model lower income and a longer re-leasing period. Capital-heavy space can need cash precisely when rent is weak. A debt-coverage ratio based only on current NOI may not capture the full cost of replacing a tenant.
Review refinancing with less remaining lease term and a more conservative value. A new loan may not repay the old one. For a DST, understand the permitted responses and the consequences of any restructuring rather than assuming ordinary operating-company flexibility. [3]
A tenant's research may be important while the property is overpriced. Review current rent, credit, improvement costs, alternative uses, and comparable transactions. The landlord does not necessarily share in the tenant's product success beyond the rights in the lease.
At sale, ask what supports the projected income and capitalization rate. A buyer may discount a building with short leases, expensive systems, or a narrow replacement-tenant pool. A high cost to build does not guarantee an equally high resale price.
Test a case with slower leasing and higher exit costs. Include fees, debt payoff, and remaining capital work. The investment should be evaluated as a real estate cash-flow plan, not as an indirect promise that scientific progress will produce investor returns.
Qualifying business or investment real property can generally be exchanged across uses. A laboratory transaction may also include movable equipment, intellectual property, licenses, or business interests. Those require separate analysis under the applicable rules. [1] [2]
A DST must fit its specific legal and tax structure. Revenue Ruling 2004-86 addresses restricted trust powers and specific facts. A plan involving major redevelopment, new borrowing, or active operations needs careful review against those limits. The property label does not establish eligibility. [3]
Coordinate identification, closing, liabilities, proceeds, costs, and Form 8824 reporting with your qualified intermediary and tax advisers. Standard deferred-exchange rules generally include 45-day identification and 180-day completion periods, with the earlier return-due-date limit and applicable relief considered. [5] [6]
Private offerings can involve limited liquidity, fees, conflicts, and substantial loss. Read the private placement memorandum and investor rights. You may not control tenant selection, capital spending, financing, or sale timing. Delegating those decisions makes the manager's capability important. [4]
Compare the investment with your cash needs and time horizon. An established laboratory leased to a well-resourced tenant differs from a speculative conversion or lease-up. A higher targeted return may reflect the extra work and uncertainty required.
I would finish with a clear explanation of the tenant's funding, the building's usefulness, the cost of the next lease, and the financing cushion. Those questions make expertise visible without pretending that a property investor can predict research outcomes.
A lease may tie rent commencement to delivery of specified space or systems. Ask which milestones control the date and who verifies them. Construction completion, system commissioning, tenant acceptance, and regulatory readiness may be different events under the documents.
Review change orders and the process for resolving disagreements. If the tenant requests a different layout or equipment connection, the parties need to know who pays and whether the schedule changes. A forecast that assumes a fixed opening date should account for the contractual conditions behind that date.
Ask for evidence that completed systems perform as intended. The investor does not need to conduct technical testing, but qualified professionals should document the relevant results. An invoice showing that equipment was purchased is not the same as confirmation that the delivered space meets the agreed requirements.
Useful reporting should show lease collections, tenant financial updates where available, capital spending, delivery milestones, and unresolved maintenance or compliance matters. Compare actual results with the underwriting assumptions. A distribution payment alone does not show whether the property's risk is increasing.
For tenants dependent on future funding, ask how the manager monitors relevant public information and required private reports. Keep confirmed financing separate from announcements or expectations. The review should update when facts change rather than carrying the original cash-runway estimate through the entire hold.
Also track the building's replacement-tenant market. New supply, sublease space, and changes in laboratory specifications can affect future options. A property that fit demand at acquisition may need extra work later. The capital and leasing plan should respond to evidence, with the effect on investor cash explained clearly.
No. The category can include research, office, testing, and production space with different requirements. Review the actual use, systems, tenants, and permits instead of treating the label as a uniform property specification.
No. The tenant still needs cash to perform. Review current resources, spending, funding commitments, guarantees, and reporting rights. The remaining lease term and the tenant's financial runway are different measures.
No. Confirm the recipient, project period, restrictions, and relationship to the legal tenant. A funding record provides context, not a guarantee of unrestricted cash or future rent. [8]
No. The cited guidance is advisory and based on risk assessment. Qualified professionals must review the actual activities, facility, approvals, and applicable requirements. A marketing description is not evidence of compliance. [7]
Design, specialized systems, construction, testing, commissions, and concessions may be needed before full rent begins. Review the scope, funding, delivery duties, and delay risk in the actual lease and budget.
No. Some systems transfer well; others fit a narrow process or require costly removal. Ask for a replacement-tenant analysis and a funded plan for vacancy, decommissioning, and new improvements.
No. Classification depends on the asset and facts. Land, building components, movable equipment, and other rights can receive different treatment. Have advisers review the purchase allocation and ownership structure. [2]
Combine a tenant funding setback, longer vacancy, higher improvement costs, and less favorable refinancing. Then check reserves and permitted responses. The model should show the cash needed to handle the problem, not only reduced rent.
Educational information, not an offer or a personal tax, legal, or investment recommendation. Examples are hypothetical and omit stated adjustments. Tax treatment depends on your facts and current law. Review your transaction with your CPA, attorney, and qualified intermediary. Real estate investments can lose value and may be illiquid.
Enter your approved email to explore investments, save your shortlist, and keep learning.